Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition
Omada Health, Inc. (OMDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition • Revenue Grew 43% and Total Members Increased 45% Year over Year, with Gross Margin Reaching a New Quarterly Record • Company Announces Sean Duffy to Become Executive Chair and Wei-Li Shao to Become Ch
How this was made
The 30-second read
Why it matters
Traders can reprice the stock based on raised revenue and adjusted EBITDA ranges plus margin expansion, while monitoring execution risk around leadership handoff and commercial rollout (including cholesterol management).
Market read
Raised FY 2026 revenue and adjusted EBITDA guidance, record gross margins, and a scheduled CEO transition create a fresh catalyst set for positioning into the next earnings cycle.
What to watch
The filing does not provide net loss outlook or GAAP-to-non-GAAP reconciliation, leaving uncertainty around GAAP profitability and warrant-related items.
Background
Omada Health filed an 8-K with Q2 2026 operating results, an updated full-year outlook, and a planned CEO transition effective Jan 1, 2027.
Ticker impact
Omada reported Q2 2026 results and raised full-year outlook, with revenue $88M (+43% YoY) and adjusted EBITDA $11M, plus CEO transition effective Jan 1, 2027.
Near-term bias to the upside on guidance/margin leverage, with volatility around the CEO transition narrative and any follow-through on 2027 revenue from new customers.
The filing discloses fresh, decision-relevant datapoints: quarterly financials, raised FY revenue and adjusted EBITDA ranges, and a scheduled executive transition with defined roles and effective date.
Market effects
Improving margins and member growth in virtual care can support sentiment for digital health and chronic-care platforms, though impact is company-specific.
Primarily US-focused commercial expansion and PBM partnerships; limited direct regional spillover.
Low global relevance beyond investor sentiment for US-listed digital health providers.
Counterpoint
Guidance strength may be partially driven by non-GAAP profitability and member growth that could face churn or reimbursement pressure, so upside may not persist.
Key entities
- public_companyOmada Health, Inc.
Nasdaq-listed virtual between-visit healthcare provider reporting Q2 2026 results and raised FY 2026 outlook, with CEO transition planned for Jan 1, 2027.
- executiveWei-Li Shao
President becoming CEO effective Jan 1, 2027, responsible for strategy and operations.
- executiveSean Duffy
Co-founder and CEO transitioning to Founder and Executive Chair effective Jan 1, 2027.
- executiveJeryl Hilleman
Board Chairperson becoming Lead Independent Director and continuing as Audit Committee Chair effective Jan 1, 2027.
